- Cambridge, MA
- Admin Support - Janet Mastrocola
- Avhana Health, Decibel Therapeutics, Gladius Pharmaceuticals, Palleon Pharma, Thrasos Therapeutics, ZappRx
Jens Eckstein is President of SR One, the corporate venture capital arm of GlaxoSmithKline. He joined SR One from TVM Capital where he was last a venture partner, entrepreneur-in-residence and appointed CEO and president of SelectX Pharmaceuticals. Prior to that, he was a general partner in TVM's Boston life sciences practice where he focused on earlier-stage investments. Jens was the founder of Akikoa Pharmaceuticals, a biotechnology start-up company focusing on hearing loss, and North Haven Systems, a life science IT company. Prior to joining TVM Capital, he led drug discovery programs at Enanta Pharmaceuticals, Inc. and Mitotix, Inc.
Jens is currently chairman of the board of directors of Thrasos Therapeutics, and a director at Palleon Pharma, Decibel Therapeutics, ZappRx, Gladius Pharmaceuticals, and BioHealth Innovation (BHI). He was previously a member of the board of directors for Alios Biosciences, CoNCERT Pharmaceuticals, Enanta Pharmaceuticals, SelectX Pharmaceuticals, Rapid Micro Biosystems, Anchor Therapeutics, and an advisor and board observer to Sirtris Pharmaceuticals.
He is the author of multiple scientific publications and holds several issued and pending patents. As a Kauffman Fellow and angel investor Jens enjoys mentoring young entrepreneurs.
Jens lives with his family in Cambridge, Massachusetts.